Associate professor Xin Cui researches ways to make drug development more efficient.
Associate professor Xin Cui researches ways to make drug development more efficient.

DENTON (UNT), Texas — A University of North Texas researcher is working to make pharmaceutical drug development more efficient and less wasteful by improving how key molecules are built.

Developing pharmaceutical drugs is a complex and costly process, especially when molecules with “handedness” are needed. These molecules, known as chiral molecules, are mirror images of each other and usually exhibit completely different biological activities. However, selectively producing a single desired form remains a significant challenge in chemical synthesis.

“Think of it like your left and right hands,” said Xin Cui, associate professor of organic chemistry in the College of Science. “They’re mirrored but can never be superimposed on top of one other. One form of the molecule would be the medicinal drug, but the other, although a mirror image, wouldn’t be effective or could even be toxic.”

Cui and his lab are researching how to solve this problem by developing new methods for direct and catalytic construction of chiral molecules. Specifically, the lab designs metal-based catalysts that enable the efficient assembly of complex molecules from readily available starting materials through the activation of strong chemical bonds that are traditionally difficult to transform. In addition, their research focuses on controlling molecular “handedness,” allowing the selective synthesis of the desired chiral form while minimizing the formation of unwanted mirror-image products.

“The two are very difficult to separate once formed, so it’s a huge waste for the pharmaceutical industry to spend resources purifying the desired form, and then essentially discarding half of the product,” Cui said.

The team works in both fundamental and applied chemistry to develop methods that can be used on a larger scale production of medicines.

“We start with simple materials that we hope are inexpensive and as abundant as possible and then quickly transform them with the catalytic systems,” Cui said. “At the same time, we control the handedness of the molecules so they are formed in the exact form needed for the final drug products. In this way, we develop new methods and then apply them to practical molecular synthesis.”

Cui and his team have extensive expertise in this research area and were recently awarded a $470,000 grant from the National Institutes of Health to advance their work. The grant is an R15 Academic Research Enhancement Award, the first ever received in the chemistry department.

“This grant has an emphasis on undergraduate education and training in the lab,” Cui said. “We welcome both UNT undergraduate and TAMS students in the lab. We also regularly attract students from other departments, such as biology and biomedical engineering, which is exciting.”

For this research, students will participate in the development of new catalysis and chemical syntheses toward valuable building blocks for drug molecules. They will learn techniques for molecule separation and purification, as well as how to determine molecular structures.

“These experiences help prepare them for future careers in the pharmaceutical industry and related medicinal industry,” Cui said. “I think it also motivates them to pursue how molecular construction eventually leads to future medicines that impact the world.”

As the team continue their work, Cui says their findings may lead to expanding research into broader areas of catalysis, creating more opportunities for advancing the science and giving students hands-on experience.

“For example, cross-coupling is a foundational methodology that has been widely applied in chemical synthesis and pharmaceutical development, but there are still new opportunities and challenges with it,” Cui said. “Because we focus on understanding the fundamental chemical processes behind catalysis, we are learning important mechanistic insights that may lead to new opportunities in other catalytic systems, including cross-coupling. The opportunities to contribute are endless.”